State supremacy in decline: The pharmaceutical industry and the Australian government

Journal of Industry Studies

Volumn 3, Issue 1, 1996, Pages 86-103

  Lofgren, Hans ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748868932     PISSN: 13206095     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. APMA 1993: Proposal for Reform of Pharmaceutical Benefits Scheme Pricing and Reimbursement. Sydney: Australian Pharmaceutical Manufacturers Association.
2. _ 1995: Submission to Industry Commission Inquiry into the Pharmaceutical Industry, Submission No. 35, 15 August.
3. _ 1996: Submission to Industry Commission Inquiry into the Pharmaceutical Industry, Submission No. 199, 18 March.
4. Aram, J.D., Lynn, L. H. and Reddy, N.M. 1992: 'Institutional relationships and technology commercialization: limitations of market-based policy', Research Policy, 21: 409-21.
5. Baume, P. 1991: A Question of Balance: Report on the Future of Drug Evaluation in Australia. Canberra: AGPS.
6. Baumheier, U. 1994: Staat und Pharmaindustrie: Sicherheitskontrolle, Preisregulierung und Industrieförderung im internationalen Vergleich. Baden-Baden: Nomos Verlagsgesellschaft.
7. Bell, G. and Callon, M. 1994: 'Techno-economic networks and science and technology policy', STI Review, No. 14: 59-117.
8. Bower, J.D. and Whittaker, E. 1993: 'Global R&D networks: the case of the pharmaceutical industry', Journal of Industry Studies, 1 (1): 50-64.
9. Bureau of Industry Economics 1991: Networks: a Third Form of Organisation. Canberra: AGPS.
10. Business Council of Australia 1995: 'Submission on the 1995-96 Commonwealth budget', Business Council Bulletin, March: 10-18.
11. Button, J. 1992: Statement on the pharmaceutical industry, Department of Industry, Technology and Commerce, 31 March.
12. Button, J. and Blewett, N. 1987: Policies for the development of die pharmaceutical products industry, Joint statement by the Minister for Industry, Technology and Commerce and the Minister for Community Services and Health, 13 September.
13. Chesnais, F. 1993: 'Globalisation, world oligopoly and some of their implications', in M. Humbert (ed) The Impact of Globalisation on Europe's Firms and Industries. London: Pinter Publishers.
14. Commonwealth Department of Human Services and Health 1995: Medicines in Australia. Canberra: AGPS.
15. Cook, P. 1995: Pharmaceutical industry: after Factor (f) another industry plan, News release 305/95, 6 September.
16. Department of Human Services and Health 1995: Submission to Industry Commission Inquiry into the Pharmaceutical Industry, Submission No. 11, 9 August.
17. Department of Industry, Technology and Regional Development 1994: [Departmental presentation] in Pharmacy Australia Yearbook 1994. Canberra: Pharmaceutical Society of Australia.
18. Dodgson, M. 1993: Technological Collaboration in Industry: Strategy, Policy and Internationalization in Innovation. London: Routledge.
19. Dower, M. 1995: 'To merge or not to merge', Scrip Magazine, No. 35: 25-26.
20. Duckett, S. 1995: Future directions: government strategies for improving quality, Address to Consumers' Health Forum National Conference on Consumers and Quality, 7 November.
21. Freeman, C. 1991: 'Networks of innovators: a synthesis of research issues', Research Policy, 20: 499-514.
22. Carving, D.A. 1995: 'Leveraging processes for strategic advantage: a roundtable with Xerox's Allaire, USAAs Herres, SmithKline Beecham's Leschly, and Pepsi's Weatherup', Harvard Business Review, 73(5): 77-90.
23. Glaxo Australia Pry Ltd 1985: Submission to the I.A.C. Inquiry into the Pharmaceutical & Veterinary Products Industries.
24. Hancher, L. 1990: Regulating for Competition: Government, Law and the Pharmaceutical Industry in the United Kingdom and France. Oxford: Clarendon Press.
25. Hansen, J.J. 1993: The regulation of Australia's pharmaceutical industry, Master of Laws thesis, Melbourne University.
26. Henderson, R. 1994: 'Managing innovation in the information age', Harvard Business Review, 72 (1): 100-105.
27. IAC 1986: Pharmaceutical Products. Canberra: AGPS.
28. Independent Committee of Inquiry into Competition Policy in Australia 1993: National Competition Policy ('Hilmer-report'). Canberra: AGPS.
29. Industry Commission 1995: The Pharmaceutical Industry: Draft Report. Melbourne: Industry Commission.
30. Jessop, B. 1993: 'Towards a Schumpeterian workfare state?: preliminary remarks on post-fordist political economy', Studies in Political Economy, No. 40: 7-39.
31. _ 1994: 'Changing forms and functions of the state in an era of globalization and regionalization', in R. Delorme and K. Dopfer (eds) The Political Economy of Diversity: Evolutionary Perspectives on Economic Order and Disorder. Aldershot: Edward Elgar.
32. Johnston, M.A. 1990: Australia's pharmaceutical pricing strategy, PhD thesis, Harvard University.
33. Kenney, M. 1986: Biotechnology: the University-Industrial Complex. New Haven: Yale University Press.
34. Kenny, M. 1994: 'Domination by the megaplayers: Jan Leschly's view of the future', Scrip Magazine, No. 29: 28-29.
35. Lundvall, B.-Å. (ed) 1992: National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning. London: Pinter Publishers.
36. Macmillan, K. and Turner, I. 1987: 'The cost-containment issue: a study of government-industry relations in the pharmaceutical sectors of the United Kingdom and West Germany', in S. Wilks and M. Wright (eds) Comparative Government-Industry Relations: Western Europe, the United States, and Japan. Oxford: Clarendon Press.
37. Nelson, R.R. 1993: National Innovation Systems: a Comparative Analysis. New York: Oxford University Press.
38. Nightingale, S. 1994: 'International harmonisation: the ICH process as a model for government and industry collaboration, Swiss Pharma, 16 (12-S): 59-63.
39. Office of Technology Assessment 1993: Pharmaceutical R&D: Costs, Risks and Rewards. Washington, DC: U.S. Government Printing Office.
40. Örn, G. 1996: 'Hȧrt jobb och tur bakom medicinsuccé', Dagens Nyheter, 16 June: C2.
41. Parry, T.G. and Creyke, P. 1991: The Australian Pharmaceutical Industry: Achievements, Prospects and the Policy Environment. Sydney: Australian Pharmaceutical Manufacturers Association.
42. Patel, P. and Pavitt, K. 1994: 'National innovation systems: why they are important, and how they might be measured and compared', Economics of Innovation and New Technology, 3(1): 77-95.
43. Pharmaceutical Manufacturing Industry Inquiry 1979: Report [Ralph report]. Canberra: AGPS.
44. 'Pharmaceuticals: a special advertising report' 1995: The Australian, 22 September, 20-21.
45. 'Prime Minister opens new MSD plant' 1994: Pharmacy 2000, 3 (6): 156-57.
46. Prince Henry's Institute of Medical Research 1995: Submission to Industry Commission Inquiry into the Pharmaceutical Industry, Submission No. 4.
47. st-Century Capitalism. London: Simon & Schuster.
48. Sally, R. 1995: States and Firms: Multinational Enterprises in Institutional Competition. London: Routledge.
49. Scrip's Yearbook 1994: Richmond, Surrey: PJB Publications.
50. Shires, D. 1995: 'New subsidy prescribed for drug R&D', Australian Financial Review, 11 September.
51. Sloan, C. 1995: A History of the Pharmaceutical Benefits Scheme 1947-1992. Canberra: Commonwealth Department of Human Services and Health.
52. SmithKline Beecham 1995: Submission to Industry Inquiry into the Pharmaceutical Industry, Submission No. 13, 10 August.
53. Streeck, W. and Schmitter, P.C. (eds) 1985: Private Interest Government: Beyond Market and State. London: SAGE.
54. Taylor, P. 1995: 'Innovation networking: a driving force in R&D', Scrip Magazine, No. 37: 42-46.
55. Vaughan, G. 1993: Speech at the APMA Annual General Meeting and Conference, September.
56. _ 1995: 'The Australian drug regulatory system', Australian Prescriber, 18 (3): 69-71.
57. Warner, J. and Dawley, H. 1995: 'Another year of magic for pills and potions', Business Week, 25 December: 66.
58. Zacher, M.W. and Sutton, B.A. 1996: Governing Global Networks: International Regimes for Transportation and Communications. Cambridge: Cambridge University Press.